Hyperactive CDK4 has been reported in epithelial malignancies in the endocrine tissues and mucosa while CDK6 activation was reported in certain mesenchymal tumors such as sarcomas and leukemias [reviewed in 1]. Here, CDK6 is linked to leukemia.